ALNY (Biotechnology) Stock Valuation & Fair Value Quality business at a reasonable price
ALNY (Biotechnology) trades at a blended P/E of 54.6, about 68% below its historical normal valuation, with a forward growth estimate of 47.7% and a PEG of 1.14. Analysts' one-year estimates have been hit 27% of the time.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is ALNY overvalued?
At a blended P/E of 54.6 versus its historical normal P/E of 170.7, ALNY trades about 68% below its typical valuation, with a PEG of 1.14 on 47.7% forward growth. tickerseer currently rates it quality business at a reasonable price.
What is ALNY's fair value and PEG?
ALNY trades at a blended P/E of 54.6 against a historical normal P/E of 170.7, a PEG of 1.14, and a forward growth estimate of 47.7%.
Has tickerseer's rating of ALNY changed?
tickerseer's rating has been quality business at a reasonable price since 2026-07-25.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.